This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Price RA Jr , Jin L , Meyer J , Chen L , Lin T , Eldib A , Chen X , Liu J , Veltchev I , Wang L , Ma C
Practical Clinical Implementation of the Special Physics Consultation Process in the Re-irradiation Environment
Adv Radiat Oncol. 2021 Jan-Feb;6(1) :100594
PMID: 33490729 PMCID: PMC7811122 URL: https://www.ncbi.nlm.nih.gov/pubmed/33490729
AbstractPURPOSE: The purpose of this work is to present a practical, structured process allowing for consistent, safe radiation therapy delivery in the re-treatment environment. METHODS AND MATERIALS: A process for reirradiation is described with documentation in the form of a special physics consultation. Data acquisition associated with previous treatment is described from highest to lowest quality. Methods are presented for conversion to equieffective dose, as well as our departmental assumptions for tissue repair. The generation of organ-at-risk available physical dose for use in treatment planning is discussed. Results using our methods are compared with published values after conversion to biologically effective dose. Utilization of pulsed-low-dose-rate delivery is described, and data for reirradiation using these methods over the previous 5 years are presented. RESULTS: Between 2015 and 2019, the number of patients in our department requiring equieffective dose calculation has doubled. We have developed guidelines for estimation of sublethal damage repair as a function of time between treatment courses ranging from 0% for <6 months to 50% for >1 year. These guidelines were developed based on available spinal cord data because we found that 84% of organs at risk involved nerve-like tissues. The average percent repair used increased from 32% to 37% over this time period. When comparing the results obtained using our methods with published values, 99% of patients had a cumulative biologically effective dose below the limits established for acceptable myelopathy rates. Pulsed-low-dose-rate use over this period tripled with an average prescription dose of 49 Gy. CONCLUSIONS: The methods described result in safe, effective treatment in the reirradiation setting. Further correlation with patient outcomes and side effects is warranted.
Notes2452-1094 Price, Robert A Jr Jin, Lihui Meyer, Joshua Chen, Lili Lin, Teh Eldib, Ahmed Chen, Xiaoming Liu, Jie Veltchev, Iavor Wang, Lu Ma, Charlie Journal Article Adv Radiat Oncol. 2020 Oct 14;6(1):100594. doi: 10.1016/j.adro.2020.09.027. eCollection 2021 Jan-Feb.